Navigation Links
Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril

us

Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.

    Lithium Interaction

    Lithium generally should not be given with thiazides.

Adverse Events

In clinical trials, the withdrawal rates due to adverse events (AEs) were similar with BENICAR and BENICAR HCT to placebo: BENICAR (2.4 percent vs 2.7 percent); BENICAR HCT (2.0 percent vs 2.0 percent). The incidence of AEs with BENICAR and BENICAR HCT were similar to placebo. The only AE that occurred in >1 percent of patients treated with BENICAR and more frequently than placebo was dizziness (3 percent vs 1 percent). AEs reported in >2 percent of patients taking BENICAR HCT and more frequently than placebo included nausea (3 percent vs 0 percent), hyperuricemia (4 percent vs 2 percent), dizziness (9 percent vs 2 percent), and upper respiratory tract infection (7 percent vs 0 percent).

No initial dosage adjustments are recommended with BENICAR in elderly, in moderate to marked renal impairment (creatinine clearance <40 mL/min), or in hepatic dysfunction. In patients with possible depletion of intravascular volume (e.g., patients on diuretics, particularly with impaired renal function), BENICAR should be initiated under close medical supervision and consideration given to use of a lower starting dose. For BENICAR HCT, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range.

Please see full prescribing information for BENICAR and BENICAR HCT.

Both products are co-promoted in the United States by Daiichi Sankyo, Inc. and Forest Laboratories, Inc.

About Daiichi Sankyo

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan's second largest pharmaceutical company and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development an
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
8. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
9. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
10. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
Post Your Comments:
(Date:9/2/2014)... According to a new market ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... of 10.1% from 2014 to 2020. Biological ... used in the treatment and prevention of various diseases ... medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... 1, 2014 Research and Markets ... Minimally-Invasive Biomarkers in Alzheimer,s Disease: A Comprehensive Analysis and ... report to their offering. This report ... developments relating to early-stage minimally-invasive biomarkers in Alzheimer,s disease, ... and candidates in the AD drug pipeline, and applicable ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2
... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , ... ... ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused on the development of small-molecule ... fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance ... ... , ...
Cached Medicine Technology:ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many ... of employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, ... to 10% off, on these useful items. , ... 20 different kinds of high end monitoring programs on ... companies of all sizes. With its high end programs, ...
(Date:9/2/2014)... A simple awareness campaign in general practice identifies new ... at ESC Congress today by Professor Jean-Marc Davy from ... the most common cardiac arrhythmia. It multiplies the risk ... of stroke risk by five-fold. Similarly, AF is responsible ... AF is often overlooked and diagnosed too late. In ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... new study finds that, despite efforts in the last ... significantly less likely than white patients to receive therapy ... study conclude that efforts to close treatment gaps initiated ... The report appears in the February 15, 2008 issue ...
... Conn., Jan. 6 Therap Services, the leading,provider ... has announced the promotion of Allison Dudo to ... responsibility of,providing help and technical guidance to users ... key part of our success, and we were ...
... heavily than male peers, field study finds , , SUNDAY, ... of college drinking behavior shows that parties with drinking ... parties encourage college women to drink more heavily than ... drinking have relied largely on individual behavior and self-reports ...
... Year,s,resolution is to lose weight, calcium and dairy can help, ... Science Hawley,Almstedt and her student Alexandra Hybki. The everyday nutrients ... down this year., People on fad diets or extreme ... foods are high in fat. Some dieters go,so far as ...
... Holdings, Inc. President Robert Oswald provides a shareholder,update., ... as we opened 5 new,locations across Canada, including the ... were fortunate to have our Official Spokesperson,for Canada, Mr. ... opening,events for our new locations. I was very pleased ...
... radiation after early-stage disease is removed, researchers say , FRIDAY, ... have not yet spread contain cells with a predisposition to ... just because a cancer has not yet spread doesn,t mean ... warned researchers at the Salk Institute for Biological Studies in ...
Cached Medicine News:Health News:Racial disparities persist in cancer care 2Health News:Therap Services Promotes Allison Dudo to Assistant Director of Training 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:Milk Does a Body and a Waistline Good 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 3Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 4Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 5Health News:Localized Breast Cancer Cells Have Potential to Spread 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: